s associated with administration of curosurf include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. these events require stopping curosurf administration and taking appropriate measures to alleviate the condition. after the patient is stable, dosing may proceed with appropriate monitoring.

r placement and patency of the endotracheal tube. at the discretion of the clinician, the endotracheal tube may be suctioned before administering curosurf. allow the infant to stabilize before proceeding with dosing. administer curosurf either: intratracheally by instillation in two divided aliquots through a 5 french end-hole catheter or intratracheally in a single bolus through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation. 2.2 recommended dosage the initial recommended dose is 2.5 ml/kg birth weight, administered as one or two aliquots depending upon the instillation procedure [see dosage and administration ( 2.4 )]. up to two repeat doses of 1.25 ml/kg birth weight each may be administered at approximately 12-hour intervals in infants in whom rds is considered responsible for their persisting or deteriorating respiratory status. the maximum recommended total dosage (sum of the initial and up to two repeat doses) is 5 ml/kg. 2.3 preparation of the curosurf suspension remove the vial of curosurf suspension from a refrigerator at +2°c to +8°c (36°f to 46°f) and slowly warm the vial to room temperature before use. visually inspect the curosurf suspension for discoloration prior to administration. the color of the curosurf suspension should be white to creamy white. discard the curosurf vial if the suspension is discolored. gently turn the vial upside-down, in order to obtain a uniform suspension. do not shake. locate the notch (flip up) on the colored plastic cap and lift the notch and pull upwards. pull the plastic cap with the aluminum portion downwards. remove the whole ring by pulling off the aluminum wrapper. remove the rubber cap to extract content. unopened, unused vials of curosurf suspension that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. do not warm to room temperature and return to refrigerated storage more than once. protect from light. 2.4 administration for endotracheal tube instillation using a 5 french end-hole catheter slowly withdraw the entire contents of the vial of curosurf suspension into a 3 or 5 ml plastic syringe through a large-gauge needle (e.g., at least 20 gauge). enter each single-use vial only once. attach the 5 french end-hole catheter of appropriate length to position the catheter tip proximal to the distal portion of the endotracheal tube, to the syringe. fill the catheter with curosurf suspension. discard excess curosurf through the catheter so that only the dose to be given remains in the syringe. for the first dose: 1.25 ml/kg (birth weight) per aliquot for each repeated dose: 0.625 ml/kg (birth weight) per aliquot first aliquot of curosurf suspension: position the infant in a neutral position (head and body in alignment without inclination), with either the right or left side dependent. immediately before curosurf administration, ventilate the infant with supplemental oxygen sufficient to maintain sao 2 > 92%. insert the catheter into the endotracheal tube and instill the first aliquot of curosurf suspension. after the first aliquot is instilled, remove the catheter from the endotracheal tube and manually ventilate with supplemental oxygen until clinically stable. second aliquot of curosurf suspension: when the infant is stable, reposition the infant such that the other side is dependent. administer the remaining aliquot using the same procedures as the first aliquot. after completion of the dosing procedure, do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur [see clinical studies ( 14.1 )] . for endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube slowly withdraw the entire contents of the vial of curosurf suspension into a 3 or 5 ml plastic syringe through a large-gauge needle (e.g., at least 20 gauge). do not attach 5 french end-hole catheter. remove the needle and discard excess curosurf so that only the dose to be given remains in the syringe. keep the infant in a neutral position (head and body in alignment without inclination). administer curosurf suspension through the proximal end of the secondary lumen of the endotracheal tube as a single dose, given over 1 minute, and without interrupting mechanical ventilation. after completion of this dosing procedure, ventilator management may require transient increases in fio 2 , ventilator rate, or pip. do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur.

from light.

rds developed and before 15 hours of age; 78 infants received curosurf 2.5 ml/kg single dose (200 mg/kg), and 66 infants received control treatment (disconnection from the ventilator and manual ventilation for 2 minutes). transient adverse reactions seen with the administration of curosurf included bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. the rates of the most common serious complications associated with prematurity and rds observed in study 1 are shown in table 1. table 1: most common serious complications associated with prematurity and rds in study 1 curosurf 2.5 ml/kg n=78 control* n=66 acquired pneumonia 17% 21% acquired septicemia 14% 18% bronchopulmonary dysplasia 18% 22% intracranial hemorrhage 51% 64% patent ductus arteriosus 60% 48% pneumothorax 21% 36% pulmonary interstitial emphysema 21% 38% *control patients were disconnected from the ventilator and manually ventilated for 2 minutes. no surfactant was instilled. seventy-six infants (45 treated with curosurf) from study 1 were evaluated at 1 year of age and 73 infants (44 treated with curosurf) were evaluated at 2 years of age to assess for potential long-term adverse reactions. data from follow-up evaluations for weight and length, persistent respiratory symptoms, incidence of cerebral palsy, visual impairment, or auditory impairment was similar between treatment groups. in 16 patients (10 treated with curosurf and 6 controls) evaluated at 5.5 years of age, the developmental quotient, derived using the griffiths mental developmental scales, was similar between groups. 6.2 immunogenicity immunological studies have not demonstrated differences in levels of surfactant-anti-surfactant immune complexes and anti-curosurf antibodies between patients treated with curosurf and patients who received control treatment. 6.3 postmarketing experience pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported both in clinical trials with curosurf and in postmarketing adverse event reports in infants who had received curosurf.

tension, endotracheal tube blockage, and oxygen desaturation. the rates of the most common serious complications associated with prematurity and rds observed in study 1 are shown in table 1. table 1: most common serious complications associated with prematurity and rds in study 1 curosurf 2.5 ml/kg n=78 control* n=66 acquired pneumonia 17% 21% acquired septicemia 14% 18% bronchopulmonary dysplasia 18% 22% intracranial hemorrhage 51% 64% patent ductus arteriosus 60% 48% pneumothorax 21% 36% pulmonary interstitial emphysema 21% 38% *control patients were disconnected from the ventilator and manually ventilated for 2 minutes. no surfactant was instilled. seventy-six infants (45 treated with curosurf) from study 1 were evaluated at 1 year of age and 73 infants (44 treated with curosurf) were evaluated at 2 years of age to assess for potential long-term adverse reactions. data from follow-up evaluations for weight and length, persistent respiratory symptoms, incidence of cerebral palsy, visual impairment, or auditory impairment was similar between treatment groups. in 16 patients (10 treated with curosurf and 6 controls) evaluated at 5.5 years of age, the developmental quotient, derived using the griffiths mental developmental scales, was similar between groups.

22% n.s. pneumothorax 21% 36% ≤0.05 pulmonary interstitial emphysema 21% 38% ≤0.05 *bronchopulmonary dysplasia (bpd) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. n.s.: not statistically significant in study 2, premature infants 700 to 2000 g birth weight with rds requiring mechanical ventilation and a fio 2 ≥ 0.60 were enrolled. in this two-arm trial, curosurf was administered after rds developed and before 15 hours of age, as a single-dose or as multiple doses. in the single-dose arm, infants received curosurf 2.5 ml/kg (200 mg/kg). in the multiple-dose arm, the initial dose of curosurf was 2.5 ml/kg followed by up to two 1.25 ml/kg (100 mg/kg) doses of curosurf. the results from study 2 are shown below in table 3. table 3: study 2 results in premature infants with respiratory distress syndrome efficacy parameter single dose curosurf n=184 rate (%) multiple dose curosurf n=173 rate (%) p-value mortality at 28 days (all causes) 21 13 0.048 bronchopulmonary dysplasia* 18 18 n.s. pneumothorax 17 9 0.03 pulmonary interstitial emphysema 27 22 n.s. *bronchopulmonary dysplasia (bpd) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. n.s.: not statistically significant there is no controlled experience on the effects of administering initial doses of curosurf other than 2.5 ml/kg (200 mg/kg), subsequent doses other than 1.25 ml/kg (100 mg/kg), administration of more than three total doses, dosing more frequently than every 12 hours, or initiating therapy with curosurf more than 15 hours after diagnosing rds. adequate data are not available on the use of curosurf in conjunction with experimental therapies of rds, e.g., high-frequency ventilation or extracorporeal membrane oxygenation.

x 21% 36% ≤0.05 pulmonary interstitial emphysema 21% 38% ≤0.05 *bronchopulmonary dysplasia (bpd) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. n.s.: not statistically significant in study 2, premature infants 700 to 2000 g birth weight with rds requiring mechanical ventilation and a fio 2 ≥ 0.60 were enrolled. in this two-arm trial, curosurf was administered after rds developed and before 15 hours of age, as a single-dose or as multiple doses. in the single-dose arm, infants received curosurf 2.5 ml/kg (200 mg/kg). in the multiple-dose arm, the initial dose of curosurf was 2.5 ml/kg followed by up to two 1.25 ml/kg (100 mg/kg) doses of curosurf. the results from study 2 are shown below in table 3. table 3: study 2 results in premature infants with respiratory distress syndrome efficacy parameter single dose curosurf n=184 rate (%) multiple dose curosurf n=173 rate (%) p-value mortality at 28 days (all causes) 21 13 0.048 bronchopulmonary dysplasia* 18 18 n.s. pneumothorax 17 9 0.03 pulmonary interstitial emphysema 27 22 n.s. *bronchopulmonary dysplasia (bpd) diagnosed by positive x-ray and supplemental oxygen dependence at 28 days of life. n.s.: not statistically significant there is no controlled experience on the effects of administering initial doses of curosurf other than 2.5 ml/kg (200 mg/kg), subsequent doses other than 1.25 ml/kg (100 mg/kg), administration of more than three total doses, dosing more frequently than every 12 hours, or initiating therapy with curosurf more than 15 hours after diagnosing rds. adequate data are not available on the use of curosurf in conjunction with experimental therapies of rds, e.g., high-frequency ventilation or extracorporeal membrane oxygenation.